Search
Atara Biotherapeutics Inc
ATRAAdd to Watchlist
11.650USD
+0.280+2.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
104.97MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.46%
5 Days
+10.85%
1 Month
+20.98%
6 Months
-34.44%
Year to Date
-35.60%
1 Year
+37.63%
Key Figures
11.500Open
12.000High
33.26KVolume
LossP/E TTM
6.82P/E Dynamic
--Dividend TTM
0.46%Turnover Ratio
11.370Prev. Close
11.410Low
271.48KTurnover
LossP/E Static
-2.29P/B
0.00%Div Yield TTM
-23.08%ROA
19.14552wk High
0.98Volume Ratio
-85.40MNet Profit
7.21MShares
-1.4123EPS TTM
0.08Beta
-2014.86%ROE
3.92052wk Low
5.19%Amplitude
75.97%Gross Margin
104.97MMarket Cap
3.10Reward/Risk
5.83%Risk Rate
TradingKey Stock Score of Atara Biotherapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Atara Biotherapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 168 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.67.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Atara Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Atara Biotherapeutics Inc Highlights
StrengthsRisks
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1308.75% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -8.25, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.70M shares, decreasing 14.85% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 87.18K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.74.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
13.667
Target Price
+20.20%
Upside Space
Atara Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Atara Biotherapeutics Inc Info
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Ticker SymbolATRA
CompanyAtara Biotherapeutics Inc
CEONguyen (Anhco)
Websitehttps://www.atarabio.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Atara Biotherapeutics Inc (ATRA)?
The current price of Atara Biotherapeutics Inc (ATRA) is 11.65.
What is the symbol of Atara Biotherapeutics Inc?
The ticker symbol of Atara Biotherapeutics Inc is ATRA.
What is the 52-week high of Atara Biotherapeutics Inc?
The 52-week high of Atara Biotherapeutics Inc is 19.14.
What is the 52-week low of Atara Biotherapeutics Inc?
The 52-week low of Atara Biotherapeutics Inc is 3.92.
What is the market capitalization of Atara Biotherapeutics Inc?
The market capitalization of Atara Biotherapeutics Inc is 84.00M.
Is Atara Biotherapeutics Inc (ATRA) currently rated as Buy, Hold, or Sell?
According to analysts, Atara Biotherapeutics Inc (ATRA) has an overall rating of Buy, with a price target of 13.67.
What is the Earnings Per Share (EPS TTM) of Atara Biotherapeutics Inc (ATRA)?
The Earnings Per Share (EPS TTM) of Atara Biotherapeutics Inc (ATRA) is 2.61.